Triazine Compounds with Morpholine for Selective mTOR Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective inhibitors for the PI3K/mTOR pathway, particularly for targeting the mTOR enzyme, which is crucial in cancer progression and chemotherapy resistance.
Innovation Solution
Development of novel triazine compounds that selectively inhibit the mTOR enzyme, either alone or in combination with PI3K, to modulate the PI3K/mTOR pathway, potentially treating breast and non-small-cell lung cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing PI3K/mTOR inhibitors are used, then some inhibition effect is achieved, but the inhibition is not selective enough and effectiveness is limited
Solution Approach 1:
The patent applies local quality by introducing a morpholine group at the 6-position of the triazine ring, which provides selective binding to mTOR while maintaining PI3K inhibition. This localized structural modification creates differential binding characteristics that enable selective mTOR inhibition without compromising PI3K activity, thereby resolving the contradiction between overall inhibition effectiveness and pathway-selective inhibition.
2Adaptability or versatility
If non-selective PI3K/mTOR inhibitors are used, then both enzymes are inhibited, but the therapeutic index is reduced and side effects increase
Solution Approach 1:
The morpholine group at the 6-position creates a local structural feature that preferentially interacts with mTOR binding pockets while having lesser impact on PI3K. This localized modification enables the compound to cover both pathways (versatility) while maintaining higher selectivity for mTOR, thereby reducing off-target effects and toxicity.
Solution Approach 2:
The compound combines a triazine core with a morpholine substituent to create a composite molecular structure. This composite structure integrates the binding characteristics of both moieties, where the triazine provides PI3K inhibition and the morpholine adds mTOR selectivity, achieving dual pathway coverage with improved safety profile.
3Adaptability or versatility
If mTOR selective inhibitors are developed, then selectivity is improved, but the complexity of molecule design increases
Solution Approach 1:
Instead of completely redesigning the molecular structure, the patent applies a local quality approach by adding only a morpholine group at the 6-position of the triazine ring. This localized modification achieves mTOR selectivity without requiring complex multi-component structures, thereby maintaining design simplicity while improving enzyme selectivity.
Data Source
AI summary
The present invention relates to novel triazine compounds of formula (1). The present invention also discloses compounds of formula I along with other pharmaceutical acceptable excipients and use of the compounds to modulate the PI3K/ mTOR pathway.